Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Safiye Dursun, MD"'
Autor:
Judith L. Gulikers, MSc, G.D. Marijn Veerman, MD, PhD, Merel Jebbink, MD, PhD, Paul D. Kruithof, PharmD, Christi M.J. Steendam, MD, PhD, René J. Boosman, PhD, Ron H.J. Mathijssen, MD, PhD, Vivianne C.G. Tjan-Heijnen, MD, PhD, Johanna H.M. Driessen, PhD, Safiye Dursun, MD, Egbert F. Smit, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Robin M.J.M. van Geel, PharmD, PhD, Sander Croes, PharmD, PhD, Lizza E.L. Hendriks, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100656- (2024)
Introduction: Brain metastases (BM) are common in patients with advanced EGFR-mutated (EGFRm+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic
Externí odkaz:
https://doaj.org/article/b8cb56c1a21d4838abe7a2a929f0a009
Autor:
Anita J.W. M. Brouns, MD, Ard van Veelen, MSc, G. D. Marijn Veerman, MD, Christi Steendam, MD, Safiye Dursun, MD, Cor van der Leest, PhD, Sander Croes, PhD, Anne-Marie C. Dingemans, MD, PhD, Lizza E.L. Hendriks, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100513- (2023)
Introduction: Bone metastases are frequent in patients with EGFR-mutated (EGFR+) NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We investigated the development
Externí odkaz:
https://doaj.org/article/95d916a897b6469bb454b001cdb7dbeb